Scarica l'app Stockscreener
188.94
1.89%
-3.63
Pre-mercato:
192.98
4.04
+2.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$192.57
Aprire:
$186.61
Volume 24 ore:
15.40M
Relative Volume:
0.92
Capitalizzazione di mercato:
$75.43B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-23.19
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
-3.02%
1M Prestazione:
+22.47%
6M Prestazione:
+277.65%
1 anno Prestazione:
+584.57%
Intervallo 1D:
$186.01
$201.00
Intervallo di 1 settimana:
$184.58
$208.90
Portata 52W:
$22.28
$208.90
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
188.94 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
506.74 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
734.81 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
936.00 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.89 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna stock after-hours at EUR 170.09: plus 0.70 percent versus the prior close - AD HOC NEWS
Moderna Stock Is Trending: What's Going On? - Benzinga
Top Healthcare Stocks To Watch TodayOctober 1st - MarketBeat
Moderna loses US government license defense in Northwestern patent case - reuters.com
Why Citi Is Sounding the Alarm on Moderna Stock - Barchart.com
Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - Yahoo Finance
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - 247wallst.com
Moderna Stock Gets Sell Call As Oncology Hopes Face Valuation Test - Simply Wall Street
The Escalator: Moderna, Hatteras Venture Partners, PhRMA and more - Medical Marketing and Media
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet - FinancialContent
Moderna adds COO role. Moderna stock falls 1.40 percent - AD HOC NEWS
Moderna, Cerebras, Jabil, HPE, Cal-Maine, Mattel, and More Stocks That Explain Today’s Market - Barron's
Moderna, Inc. Announces Management Changes - marketscreener.com
Why Moderna (MRNA) Shares Are Falling Today - Yahoo Finance
This Analyst Just Downgraded Moderna Stock. Here's Why. - Yahoo Finance
Citi Downgrades Moderna Stock, Warning $80 Billion Valuation Asks Too Much of Cancer Pipeline - Barron's
Moderna Stock Slumps as Citi Says It’s Time to Sell After 500% Rally This Year - Investopedia
Moderna Shares Reverse Weakness, Rise Over 3% After Key Trading Signal - Benzinga
Citi delivers major verdict after Moderna’s remarkable 703% run - thestreet.com
Prediction: Moderna Stock Will Soar 100% by 2030 - Yahoo Finance
Prediction: Moderna Stock Will Soar 100% by 2030 - The Motley Fool
What's Going On With Moderna Stock on Wednesday? - Benzinga
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - Zacks Investment Research
Moderna Tumbles as Citi Advises Selling Following 600% Rally - Bloomberg.com
Moderna (MRNA) Options Traders Turn Moderately Bearish Amid Pric - GuruFocus
Moderna (NASDAQ:MRNA) Shares Gap DownHere's Why - MarketBeat
Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter - Barron's
Citi tells investors it’s time to sell Moderna after 600%-plus stock gains - MarketWatch
Moderna (MRNA) Shares Drop 6.88% Premarket After Citi Downgrade Citing Valuation Concerns - GuruFocus
Moderna Inc Stock (MRNA) Opened Down by 6.27% on Sep 30: Key Drivers Unveiled - TradingKey
Three biotech updates, including accusations of theft and and a new lobbying leader - statnews.com
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat - Yahoo Finance
Target upgraded, Moderna downgraded: Wall Street's top analyst calls - Yahoo Finance
MRNA Stock Downgraded As Valuation Fears Eclipse Cancer Win - StocksToTrade
MRNA Stock Downgraded As Valuation Fears Clash With Trial Success - timothysykes.com
Moderna (MRNA) Shares Fall Premarket After Citi Downgrades to Se - GuruFocus
MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum - Yahoo Finance
Premarket movers: Micron; Boeing rises, Moderna slides - Yahoo Finance
Moderna Names Juan Andres as COO - marketscreener.com
Moderna stock slips as Citi cuts to Sell (MRNA:NASDAQ) - Seeking Alpha
Moderna: Citi says oncology optimism is priced in, cuts rating to sell - Yahoo! Finance Canada
Citi Downgrades Moderna Stock after 222% Rally, Calls Oncology Expectations “Unrealistic” - TipRanks
Moderna names Juan Andres chief operating officer - TradingView
Moderna names Juan Andres as chief operating officer - Investing.com
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology - ACCESS Newswire
Moderna, Inc. (MRNA) Adds COO; Andres Returns, Collins Retires - TradingView
Citigroup Downgrades Moderna to Sell From Neutral, Adjusts Price Target to $80 From $60 - marketscreener.com
Moderna Sets Another Fresh 52-Week High: What's Happening? - Benzinga
Bayer Advances Patent Suit Over Moderna, Pfizer Covid Vaccines - Bloomberg Law News
Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion (NASDAQ:MRNA) - Seeking Alpha
Precision Trading with Moderna Inc. (MRNA) Risk Zones - Stock Traders Daily
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Sep 15 '26 |
Option Exercise |
12.21 |
76,452 |
933,479 |
1,602,310 |
| Hoge Stephen | President |
Sep 15 '26 |
Sale |
146.07 |
40,281 |
5,883,846 |
1,562,029 |
| Hoge Stephen | President |
Sep 14 '26 |
Sale |
144.13 |
40,294 |
5,807,574 |
1,525,858 |
3.09%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):